Recommendation ID
CG175/2
Question
Androgen deprivation therapy and/or brachytherapy added to radiotherapy for men with intermediate- and high-risk localised non-metastatic prostate cancer:- Does the addition of androgen deprivation therapy and/or brachytherapy to high-dose external beam radiotherapy improve outcomes for men with intermediate- and high-risk localised non-metastatic prostate cancer? Outcomes of interest are biochemical disease-free survival, metastasis-free survival, overall survival, side effects and quality of life. [new 2014]
Any explanatory notes
(if applicable)
Why this is important:- There is insufficient evidence on the effectiveness of adding androgen deprivation therapy or brachytherapy, or both, to external beam radiotherapy (using current optimal techniques) in men with intermediate- and high-risk localised non-metastatic prostate cancer.
Randomised controlled trials should compare the effectiveness of the following:
- external beam radiotherapy combined with androgen deprivation therapy
- external beam radiotherapy combined with brachytherapy
- external beam radiotherapy combined with androgen deprivation therapy and brachytherapy
- external beam radiotherapy alone.

Source guidance details

Comes from guidance
Prostate cancer: diagnosis and management
Number
CG175
Date issued
January 2014

Other details

Is this a recommendation for the use of a technology only in the context of research? No  
Is it a recommendation that suggests collection of data or the establishment of a register?   No  
Last Reviewed 07/03/2014